NeuroNova AB
This article was originally published in Start Up
Executive Summary
Sweden's NeuroNova has identified a convenient and accessible source of neural stem cells in the ependymal layer of the brain. The company hopes to use such cells for transplantation therapy in Parkinson's disease and as a platform for drug discovery.
You may also be interested in...
Stem Cells: What's the Business Model?
The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.
Stem Cells: What's the Business Model?
The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.
Faust Pharmaceuticals
Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.